Conferences

Patients with chronic lymphocytic leukemia (CLL) who are relapsed or refractory (R/R) to ibrutinib or idelalisib may benefit from venetoclax.
Investigators assessed how response rate changed when patients were treated with different doses of brigatinib.
Researchers conducted a study to generate estimates of costs associated with breast cancer adjuvant chemotherapy regimens.
Researchers developed a model to estimate the cost per month of survival in patients treated with daratumumab, carfilzomib, and pomalidomide plus dexamethasone.
Prolonging platinum-free interval by introducing non-platinum-based chemotherapy may actually worsen efficacy outcomes in patients with recurrent ovarian cancer.
In a trial of patients receiving nivolumab plus ipilimumab or a placebo plus ipilimumab, survival in patients who discontinued use due to toxicity was observed.
Using a web application developed by French researchers may help clinicans to better manage follow-up for patients with lung cancer.
Patients with metastatic castrate resistant prostate cancer treated with enzalutamide may experience central nervous system adverse events.
Representatives from American Society of Clinical Oncology and the European CanCer Organisation discussed strategies for delivering more value-based care.
Health-related quality of life and its impact on disease progression should be a consideration when selecting treatment for sarcoma.